<p>根據公司在最近向證券交易委員會的披露，Kennedy Capital Management LLC 在第二季度將其在 Capricor Therapeutics, Inc.（NASDAQ:CAPR - 免費報告）的持股減少了 51.1%。該基金在季度內出售了 78,468 股後，持有 75,019 股該生物技術公司的股票。Kennedy Capital Management LLC 在最近一個季度末持有的 Capricor Therapeutics 的股份約佔 0.16%，價值 74.5 萬美元。</p>
<p>獲取 <strong>Capricor Therapeutics</strong> 的提醒：</p>
<ul>
<li>Capricor Therapeutics 上漲超過 100%，可能會進一步上漲</li>
</ul>
<p>其他機構投資者和對沖基金也對該公司的持倉進行了調整。Rhumbline Advisers 在第二季度將其在 Capricor Therapeutics 的持倉增加了 7.3%。Rhumbline Advisers 現在持有 53,450 股該生物技術公司的股票，價值 53.1 萬美元，此前在上個季度購買了 3,636 股。Legal &amp; General Group Plc 在第二季度將其在 Capricor Therapeutics 的股份增加了 8.4%。Legal &amp; General Group Plc 現在持有 41,273 股該生物技術公司的股票，價值 41 萬美元，此前在上個季度購買了 3,205 股。Citizens Financial Group Inc. RI 在第二季度將其在 Capricor Therapeutics 的股份增加了 249.2%。Citizens Financial Group Inc. RI 現在持有 35,000 股該生物技術公司的股票，價值 34.8 萬美元，此前在上個季度購買了 24,977 股。Geode Capital Management LLC 在第二季度將其在 Capricor Therapeutics 的股份增加了 6.8%。Geode Capital Management LLC 現在持有 963,080 股該生物技術公司的股票，價值 956.5 萬美元，此前在上個季度購買了 61,701 股。最後，Simplify Asset Management Inc.在第二季度購買了 Capricor Therapeutics 的新股份，價值約 39.7 萬美元。目前，21.68% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>分析師評級升級與降級</h2>
<p>多家券商最近對 CAPR 發佈了報告。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Capricor Therapeutics 股票的 “賣出（d-）” 評級。Maxim Group 在週四將 Capricor Therapeutics 的目標價從 25.00 美元提高至 50.00 美元，並給予該股票 “買入” 評級。Alliance Global Partners 在 12 月 3 日的研究報告中重申了對 Capricor Therapeutics 股票的 “買入” 評級。Oppenheimer 在週一將 Capricor Therapeutics 的目標價從 22.00 美元提高至 54.00 美元，並給予該股票 “跑贏大盤” 評級。最後，HC Wainwright 在 12 月 3 日的研究報告中將 Capricor Therapeutics 的目標價從 24.00 美元提高至 60.00 美元，並給予該股票 “買入” 評級。一位投資分析師對該股票給予了強烈買入評級，八位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 34.50 美元。</p>
<p><strong>查看我們關於 CAPR 的最新研究報告</strong></p>
<h2>Capricor Therapeutics 價格表現</h2>
<p>NASDAQ CAPR 在週二開盤價為 28.56 美元。Capricor Therapeutics, Inc.的 1 年最低價為 4.30 美元，1 年最高價為 40.37 美元。該公司的 50 日簡單移動平均線為 8.01 美元，200 日簡單移動平均線為 8.34 美元。該公司的市值為 13.1 億美元，市盈率為-15.87，貝塔值為 0.62。</p>
<p>Capricor Therapeutics（NASDAQ:CAPR - 獲取免費報告）在 11 月 10 日最後發佈了其財報。該生物技術公司報告本季度每股收益（EPS）為（0.54 美元），符合分析師的共識預期（0.54 美元）。平均而言，股票研究分析師預計 Capricor Therapeutics, Inc.在當前財政年度將發佈-1.21 的每股收益。</p>
<h2>Capricor Therapeutics 公司簡介</h2>
<p>（免費報告）</p>
<p>Capricor Therapeutics, Inc NASDAQ: CAPR 是一家臨牀階段的生物技術公司，專注於發現、開發和商業化用於治療罕見疾病的一流生物治療藥物。Capricor 的主要候選藥物 CAP-1002 是一種同種異體細胞療法，目前正在進行臨牀開發，以治療杜氏肌營養不良症。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Capricor Therapeutics</li>
<li>股票平均計算器</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的影響</li>
<li>工業產品股票投資</li>
<li>2026 年最有可能拆分的 3 只股票</li>
<li>3 只提供優厚股息收益的天然氣股票</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次上漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Capricor Therapeutics 嗎？</h2>
<p>在你考慮 Capricor Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Capricor Therapeutics 並不在名單上。</p>
<p>雖然 Capricor Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Capricor治療

<p>肯尼迪資本管理公司在第二季度將其在 Capricor Therapeutics 的股份減少了 51.1%。儘管如此，其他機構投資者卻增加了他們的持倉。分析師們的評級不一，普遍目標價為 34.50 美元。Capricor 的股票開盤價為 28.56 美元，市值為 13.1 億美元。該公司專注於針對罕見疾病的生物治療，CAP-1002 正在進行杜氏肌營養不良症的臨牀開發</p>

<p>Kennedy Capital Management LLC trimmed its stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 51.1% in the second quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 75,019 shares of the biotechnology company's stock after selling 78,468 shares during the quarter. Kennedy Capital Management LLC owned approximately 0.16% of Capricor Therapeutics worth $745,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根據公司在最近向證券交易委員會的披露，Kennedy Capital Management LLC 在第二季度將其在 Capricor Therapeutics, Inc.（NASDAQ:CAPR - 免費報告）的持股減少了 51.1%。該基金在季度內出售了 78,468 股後，持有 75,019 股該生物技術公司的股票。Kennedy Capital Management LLC 在最近一個季度末持有的 Capricor Therapeutics 的股份約佔 0.16%，價值 74.5 萬美元。</p>
</div><p>Get <strong>Capricor Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Capricor Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>Capricor Therapeutics 上漲超過 100%，可能會進一步上漲</li>
</ul>
</div><p>Other institutional investors and hedge funds have also made changes to their positions in the company. Rhumbline Advisers increased its position in Capricor Therapeutics by 7.3% during the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company's stock worth $531,000 after purchasing an additional 3,636 shares in the last quarter. Legal &amp; General Group Plc boosted its stake in shares of Capricor Therapeutics by 8.4% during the 2nd quarter. Legal &amp; General Group Plc now owns 41,273 shares of the biotechnology company's stock worth $410,000 after purchasing an additional 3,205 shares during the last quarter. Citizens Financial Group Inc. RI boosted its stake in shares of Capricor Therapeutics by 249.2% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 35,000 shares of the biotechnology company's stock worth $348,000 after purchasing an additional 24,977 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Capricor Therapeutics by 6.8% in the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company's stock valued at $9,565,000 after buying an additional 61,701 shares during the last quarter. Finally, Simplify Asset Management Inc. purchased a new position in shares of Capricor Therapeutics during the second quarter valued at approximately $397,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金也對該公司的持倉進行了調整。Rhumbline Advisers 在第二季度將其在 Capricor Therapeutics 的持倉增加了 7.3%。Rhumbline Advisers 現在持有 53,450 股該生物技術公司的股票，價值 53.1 萬美元，此前在上個季度購買了 3,636 股。Legal &amp; General Group Plc 在第二季度將其在 Capricor Therapeutics 的股份增加了 8.4%。Legal &amp; General Group Plc 現在持有 41,273 股該生物技術公司的股票，價值 41 萬美元，此前在上個季度購買了 3,205 股。Citizens Financial Group Inc. RI 在第二季度將其在 Capricor Therapeutics 的股份增加了 249.2%。Citizens Financial Group Inc. RI 現在持有 35,000 股該生物技術公司的股票，價值 34.8 萬美元，此前在上個季度購買了 24,977 股。Geode Capital Management LLC 在第二季度將其在 Capricor Therapeutics 的股份增加了 6.8%。Geode Capital Management LLC 現在持有 963,080 股該生物技術公司的股票，價值 956.5 萬美元，此前在上個季度購買了 61,701 股。最後，Simplify Asset Management Inc.在第二季度購買了 Capricor Therapeutics 的新股份，價值約 39.7 萬美元。目前，21.68% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級升級與降級</h2>
</div><p>A number of brokerages recently issued reports on CAPR. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Capricor Therapeutics in a research report on Wednesday, October 8th. Maxim Group raised their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday. Alliance Global Partners reaffirmed a &#34;buy&#34; rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Oppenheimer increased their target price on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an &#34;outperform&#34; rating in a research report on Monday. Finally, HC Wainwright raised their price target on Capricor Therapeutics from $24.00 to $60.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $34.50.</p>
<div class="lb-trans"><p>多家券商最近對 CAPR 發佈了報告。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Capricor Therapeutics 股票的 “賣出（d-）” 評級。Maxim Group 在週四將 Capricor Therapeutics 的目標價從 25.00 美元提高至 50.00 美元，並給予該股票 “買入” 評級。Alliance Global Partners 在 12 月 3 日的研究報告中重申了對 Capricor Therapeutics 股票的 “買入” 評級。Oppenheimer 在週一將 Capricor Therapeutics 的目標價從 22.00 美元提高至 54.00 美元，並給予該股票 “跑贏大盤” 評級。最後，HC Wainwright 在 12 月 3 日的研究報告中將 Capricor Therapeutics 的目標價從 24.00 美元提高至 60.00 美元，並給予該股票 “買入” 評級。一位投資分析師對該股票給予了強烈買入評級，八位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 34.50 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on CAPR</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CAPR 的最新研究報告</strong></p>
</div><h2>Capricor Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Capricor Therapeutics 價格表現</h2>
</div><p>NASDAQ CAPR opened at $28.56 on Tuesday. Capricor Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $40.37. The business's 50-day simple moving average is $8.01 and its 200-day simple moving average is $8.34. The firm has a market capitalization of $1.31 billion, a P/E ratio of -15.87 and a beta of 0.62.</p>
<div class="lb-trans"><p>NASDAQ CAPR 在週二開盤價為 28.56 美元。Capricor Therapeutics, Inc.的 1 年最低價為 4.30 美元，1 年最高價為 40.37 美元。該公司的 50 日簡單移動平均線為 8.01 美元，200 日簡單移動平均線為 8.34 美元。該公司的市值為 13.1 億美元，市盈率為-15.87，貝塔值為 0.62。</p>
</div><p>Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, meeting analysts' consensus estimates of ($0.54). On average, equities research analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Capricor Therapeutics（NASDAQ:CAPR - 獲取免費報告）在 11 月 10 日最後發佈了其財報。該生物技術公司報告本季度每股收益（EPS）為（0.54 美元），符合分析師的共識預期（0.54 美元）。平均而言，股票研究分析師預計 Capricor Therapeutics, Inc.在當前財政年度將發佈-1.21 的每股收益。</p>
</div><h2>Capricor Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Capricor Therapeutics 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.</p>
<div class="lb-trans"><p>Capricor Therapeutics, Inc NASDAQ: CAPR 是一家臨牀階段的生物技術公司，專注於發現、開發和商業化用於治療罕見疾病的一流生物治療藥物。Capricor 的主要候選藥物 CAP-1002 是一種同種異體細胞療法，目前正在進行臨牀開發，以治療杜氏肌營養不良症。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Capricor Therapeutics</li>
<li>Stock Average Calculator</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>Industrial Products Stocks Investing</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Capricor Therapeutics</li>
<li>股票平均計算器</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的影響</li>
<li>工業產品股票投資</li>
<li>2026 年最有可能拆分的 3 只股票</li>
<li>3 只提供優厚股息收益的天然氣股票</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次上漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CAPR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Capricor Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Capricor Therapeutics 嗎？</h2>
</div><p>Before you consider Capricor Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Capricor Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Capricor Therapeutics 並不在名單上。</p>
</div><p>While Capricor Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Capricor Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Kennedy Capital Management LLC 減少了其在 Capricor 治療公司（Capricor Therapeutics, Inc.）$CAPR 的持倉